Intensifying R&D Competition and Uncertainty over Investment Returns
First written in FY2017. 4 of 5 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2026: 14 of 29 companies on the "Worse" side.
74 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「Competition among contact lens products is intense, and we recognize that there is a reasonable possibility that this risk will materialize.」
Intensifying R&D competition and uncertainty over commercialization speed and investment returns continue to be treated as important risks. - FY2022RestatedAnnual report
「Competition among contact lens products is intense, and we recognize that there is a reasonable possibility that this risk will materialize.」
R&D competition, commercialization speed and uncertainty over investment returns continue to be treated as important risks. - FY2021RestatedAnnual report
「Competition with other companies has intensified in R&D in recent years, increasing the importance of R&D and patent strategies.」
Intensifying R&D competition and uncertainty over commercialization speed and investment returns continue to be treated as important risks. - FY2019RestatedAnnual report
「Competition with other companies has intensified in R&D in recent years, increasing the importance of R&D and patent strategies.」
Intensifying R&D competition and uncertainty over commercialization speed and investment returns continue to be treated as important risks. - FY2017First statedAnnual report
「Competition with other companies has intensified in R&D in recent years, increasing the importance of R&D and patent strategies. In this environment, the contact lens industry is structured so that the speed of R&D directly affects corporate competitiveness, and our Group recognizes bringing products to market quickly as an important management issue common to all its businesses. However, contact lens development requires a long period comparable to that for pharmaceuticals, from basic research through clinical trials and commercialization. If R&D investments fail to produce the expected results, this could affect our Group’s financial position and operating results.」
Intensifying R&D competition, delays in commercialization, longer periods from basic research to commercialization and failure to achieve expected investment returns are explicitly identified as interconnected risks.